Abeona Therapeutics Provides Regulatory Update on Pz-cel
April 22, 2024 16:05 ET
|
Abeona Therapeutics Inc.
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new...
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024 07:49 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery...
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 08, 2024 13:30 ET
|
Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 03, 2024 06:30 ET
|
Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024 08:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, April 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry
March 25, 2024 07:48 ET
|
MetasTx LLC
Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
March 21, 2024 07:58 ET
|
CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
March 18, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving...
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
March 14, 2024 05:00 ET
|
S. M. Discovery Group (SMDG)
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...